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Biologic Treatments for Sports
Injuries II Think Tank—Current
Concepts, Future Research, and
Barriers to Advancement, Part 3
Articular Cartilage
Jason P. Zlotnicki,* MD, Andrew G. Geeslin,‡ MD, Iain R. Murray,§ MD, PhD,
Frank A. Petrigliano,|| MD, Robert F. LaPrade,{# MD, PhD, Barton J. Mann,†** PhD,
and Volker Musahl,* MD
Investigation performed at Steadman Philippon Research Institute, Vail, Colorado, USA
Focal chondral defects of the articular surface are a common occurrence in the field of orthopaedics. These isolated cartilage
injuries, if not repaired surgically with restoration of articular congruency, may have a high rate of progression to posttraumatic
osteoarthritis, resulting in significant morbidity and loss of function in the young, active patient. Both isolated and global joint
disease are a difficult entity to treat in the clinical setting given the high amount of stress on weightbearing joints and the limited
healing potential of native articular cartilage. Recently, clinical interest has focused on the use of biologically active compounds
and surgical techniques to regenerate native cartilage to the articular surface, with the goal of restoring normal joint health and
overall function. This article presents a review of the current biologic therapies, as discussed at the 2015 American Orthopaedic
Society for Sports Medicine (AOSSM) Biologics Think Tank, that are used in the treatment of focal cartilage deficiencies. For each
of these emerging therapies, the theories for application, the present clinical evidence, and specific areas for future research are
explored, with focus on the barriers currently faced by clinicians in advancing the success of these therapies in the clinical setting.
Keywords: chondral defects; platelet-rich plasma; mesenchymal stem cells; growth factors; scaffolds
Focal articular cartilage defects greater than 1.5 cm in dia-
meter, if left untreated, may eventually progress to osteoar-
thritis (OA). OA represents a progressive decline in the
articular surface of weightbearing joints. An arthritic joint
can be the end result of chronic ‘‘wear and tear’’ injury char-
acterized by repetitive use or as a result of a traumatic
injury. Both mechanisms are initiated by focal, sometimes
diffuse, areas of cartilage injury and degeneration, which
propagates joint destruction through inflammatory
mechanisms. Cartilage injuries are common, affecting 27
million people in the United States according to data from
2005.56 Of people aged 18 to 44 years, 7.3% report diagnosed
arthritis; in those 45 to 64 years, 30.3% report diagnosed
arthritis; and in persons aged 65 years or older, 49.7% report
diagnosed arthritis. This statistic highlights that with an
increasing proportion of older patients seekingmedical care
for joint pathology, a need for early detection of cartilage
defects and novel repair strategies has never been more
important in preventing morbidity and maintaining mobi-
lity of the aging population. The unique structure of articu-
lar cartilage and the osteochondral unit has proven difficult
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for creating an optimal biologic agent to reverse the progres-
sive nature of articular destruction as well as function to
repair isolated cartilage defects. It is well understood that
articular cartilage grows and maintains without blood ves-
sels or innervation and most importantly, with a limited
capacity for healing and repair after injury.32 Chondrocytes
have a limited potential for replication or migration to a site
of injury,mainly due to their role in preserving a localmicro-
environment of extracellular matrix of collagens, proteins,
lipids, and water. Therefore, the successful treatment of
articular injurywith biologic therapiesmust be highly effec-
tive in replicating the anatomic architecture of the joint sur-
face and must be able to inherently withstand or otherwise
restore resiliency of the cartilage to biomechanical forces.
The biologic therapies currently available for use havewide-
spread but variable evidence to support their clinical use at
present. The current organization and treatment indica-
tions of these techniques is based on the size and location
of the cartilage lesion as well as functional demands of the
patient receiving treatment.15
STIMULATION AND MODIFICATION
OF THE NATIVE ARTICULAR CHONDROCYTES
Despite the biomechanical stresses placed on the articular
surface, there is limited potential for regrowth or repair of
full-thickness cartilage defects. Biologic stimulation using
cytokinesandgrowthfactors isapromisingareatoenhancethe
articular surface’s inherent ability to survive and repopulate.
Through paracrine signaling cascades, enhancement of the
genetic expression of chondrocytes, or stimulation and recruit-
ment of mesenchymal stem cells that may gain access to the
joint in time of acute injury, and small biological compounds or
procedureswith an intra-articular site of action are an exciting
target for cartilage repair and regeneration.
A technique solely focused on cellular recruitment—
microfracture surgery without additional biologic aug-
mentation—is used mainly for the treatment of small
lesions (<2 to 4 cm2).35 In comparison with osteochondral
autograft transfer (OAT) procedures, microfracture
demonstrates similar clinical outcomes at intermediate-
term follow-up. However, it is important to note that OAT
patients have been reported in a retrospective study to
maintain a superior level of athletic activity compared
with those treated with microfracture.55 The addition of
combination growth factor substrates, such as bone mar-
row aspirate, have been shown by Fortier et al31 to signif-
icantly improve the ability of microfracture to heal full-
thickness defects in an animal model. Also, recent studies
into the biologic mediators of the fibrotic, non–type II col-
lagenous response generated by microfracture and acute
joint trauma has shown 2molecules (lysophosphatidic acid
[LPA] and autotaxin [ATX]) that are involved in the feed-
back toward collagen type I (COL1) or collagen type II
(COL2) production. Small molecule inhibitors signifi-
cantly reduced the quantity of COL1-enriched fibrocarti-
lage products with a concomitant increase in COL2
associated with the healthy cartilage state.90 Therefore,
further study into the cascade of ineffective fibrotic cartilage
therapy and the role ofwidespread growth factor induction to
migrating progenitor cells may increase the indications for
and the quality of microfracture surgery.
With regard to the addition of growth factors, the most
thoroughly investigated compounds are transforming
growth factor–b1 (TGFb1), bone morphogenetic protein
(BMP7), and insulin-like growth factor-1 (IGF1).29 TGFb1,
BMP7, and IGF1 have all been shown in in vitro studies to
increase chondrocyte synthetic activity and enhancematrix
deposition while decreasing the catabolic activity of
interleukin-1 (IL1), a widespread inflammatory cytokine
implicated in the progressive destruction of an osteoar-
thritic joint.8,24 Other compounds in the TGFb family have
demonstrated potential with in vitro study.82 However,
TGFb1 has been implicated in these same studies for the
stimulation of synovium, development of fibrosis, and the
induction of osteophyte formation, and therefore is not a
presently viable therapy for intra-articular use. At this
time, BMP7 has emerged as an ideal factor for the regen-
eration of articular cartilage due to its anabolic yet anti-
inflammatory effect, its function independent of chondro-
cyte age or OA, and its ability to function synergistically
with other factors such as IGF1.13,24,58 In addition, there
have been several growth factors studied independently
and in combination with other factors (ie, BMP7 and
IGF1).29 Chondrogenesis is known to be regulated during
development by multiple growth signals that exhibit syner-
gistic, anticatabolic, and paracrine components. This devel-
opmental paradigm has been described as the blueprint for
the engineering of chondrocytes from pluripotent cells and
is therefore of great importance.89 The presence of multiple
growth factors interacting in specific concentrations and
gradients within the active region of cartilage during devel-
opment has turned the focus for therapies to autologous,
mixed biologics that are known to contain a combination
of growth factors, such as platelet-rich plasma (PRP).
PRP is an autologous, highly concentrated product con-
taining both growth factors and inflammatory mediators.
Review of the literature shows a widely documented ability
to enhance chondrocyte proliferation80,91 while its effects
on the differentiation and productivity of chondrocytes has
been less consistently documented. Certain studies have
demonstrated increased cell proliferation, upregulation,
and increased synthesis of proteoglycan and COL2 effective
in establishing matrix formation.9,30,57,64 Other authors
have argued that PRP is unable to induce a deposition of
matrix components with no difference in extracellular
matrix (ECM) formation observed when compared with
other platelet and whole blood partitions.23,45 This has sig-
nificant implications for ability to restore and produce a
resilient articular surface. The inconsistency in reports
may be attributable to several known factors. The studies
aforementioned were performed in different cell types with
varying study designs, and it has been well documented
that significant differences in platelet and leukocyte con-
centration and growth factor composition between PRP
preparations exist and can result in significant physiologic
differences when studied.4,11,52,63 In one such study, leu-
kocyte- and platelet-rich plasma (L-PRP), a preparation
with higher platelet concentration and leukocytes,
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significantly elevated pro-inflammatory cytokines and
inhibited anticatabolic substrates when compared with
pure PRP (P-PRP), a lower concentration pure platelet
preparation.4 An in vitro study developed by Cavallo
et al11 for the comparison of different PRP formulations
demonstrated that L-PRP and P-PRP induce distinctly
different genetic effects on chondrocytes due to different
concentrations of platelets, leukocytes, growth factors,
and other bioactive molecules. The specific concentration
of active elements within PRP and how they affect the
knee articular surface is a controversial topic. Compari-
sons of therapeutic effect with single- versus double-
spinning techniques show that double-spin techniques
tend to generate pain and swelling, with similar and sig-
nificant clinical improvement observed with both thera-
pies.27 Therefore, double-spinning may concentrate
factors to a level that serves as locally proinflammatory.
More research into the optimal preparation technique for
an ideal PRP formulation is needed. When reported in the
literature, the findings of a particular study must discuss
the process of production and characterize the composition
of biologic compound to aid in the standardization and
reproducibility of results.67 Recent high-level evidence has
compared PRP injections with placebo (saline) and PRP
with intra-articular hyaluronic acid (HA) injection. In the
former, with 156 knees randomized to P-PRP versus a
single saline injection, it was reported that there was a
short-term effectiveness of PRP injections over placebo for
relief of pain and improvement in knee function as por-
trayed by Western Ontario and McMaster Universities
Arthritis Index (WOMAC) subscores. In comparison with
HA, multiple studies have demonstrated improvement in
functional scores with both HA and PRP, but a signifi-
cantly greater improvement with longer efficacy was
noted in the PRP group.12,43 Younger and more active
patients with low-grade degenerative changes tend to
receive significant improvement and better clinical
improvement compared with more degenerative joints
observed in older patients.27,43,51 However, recent studies
by Filardo et al have shown no significant difference
between PRP and HA injection26 and have refuted previ-
ous evidence that PRP was superior in middle-aged
patients with moderate to advanced OA.27 Therefore, a
conclusion is not readily apparent at this time. Other stud-
ies suggest that PRP may not be sufficient in itself to pro-
duce a regenerative structure but that the addition of PRP
as a molecular signal increases the subchondral progeni-
tor population released into the joint during microfracture
or injury. These stimulatory effects have been documented
in cell culture53,54 and promote the use of PRP as an aug-
ment to scaffold or resident cell populations that migrate
into the joint during injury or marrow stimulation tech-
niques.73,80 Research conclusions derived from basic sci-
ence and clinical trials, well discussed in a recent review
by Xie et al,91 collectively show PRP as a promising treat-
ment and adjunct to the management of cartilage injuries.
In this recent review, the positive mechanisms that show
promise for isolated cartilage repair and the reversal of
osteoarthritic processes are (1) the anabolic effect on chon-
drocytes, mesenchymal stem cells, and synoviocytes with
resultant increases in cell proliferation, ECM accumula-
tion, and HA secretion; (2) PRP may act as a bioactive cell
scaffold as clot formation occurs to physically bridge
full-thickness defects and increase cartilage regeneration;
and finally (3) PRP may serve to inhibit inflammation
and alleviate OA symptoms, with decreased pain and
improved function, with a clinically acceptable safety pro-
file.91 In addition to this review, the anti-inflammatory
properties have been well documented along with the abil-
ity of PRP to modulate pain, leading to increased function
and better symptomatic management of OA.81,83 In order
for more high-level studies to emerge, consistent attention
must be paid to the specific components in each study’s PRP
preparation and the specifics of study design. A review of
the pros, cons, and specific areas needed for future study in
the use of PRP in research and clinical treatment of symp-
tomatic cartilage defects is provided in Table 1.
CLINICAL APPLICATION OF
IN VITRO–ENGINEERED IMPLANTS
For defects too large or complex for direct stimulation with
subchondral (microfracture) or growth factor stimulation
(BMP7, TGFb, PRP, etc), the implementation of autologous
chondrocyte implantation (ACI) has been shown to be effec-
tive when compared with microfracture or osteochondral
autograft transplantation. The originally described ACI
TABLE 1
Pros, Cons, and Specific Areas Needed for Future Study
in the Use of PRP in Research and Clinical Treatment
of Symptomatic Cartilage Defectsa
Pros
 Easy to administer in clinical practice
 Stimulates proliferation of native chondrocytes, MSCs, and
synovium
 Active component demonstrates anti-inflammatory effects
 Nociceptive effect in symptomatic OA
 Can be used in conjunction with other joint restoration
techniques
Cons
 Unable to add factors (or otherwise modify) to PRP for
reinjection
 Multiple systems in use with considerable variability
 Optimal platelet concentration, leukocyte content, or factor
profile not yet clear
 No standardized dosing protocol
 Ideal host (ie, age, health status, activity level) not yet clear
Needs for future study
 Improved characterization of active elements
 Standard concentration of active molecules, leukocytes, and
dosing regimen
 Large-scale, prospective, multicenter trials needed for
outcome evidence
 Improved national and international collaboration in
research
 Collaboration with governing bodies to promote scientific
advancement
aMSCs, mesenchymal stem cells; OA, osteoarthritis; PRP,
platelet-rich plasma.
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procedure requires a2-step surgical approach,withharvest-
ing of a section of articular cartilage, amplification, and
eventual reintroduction with a periosteal flap into the pre-
pared chondral defect. First introduced in 1994, this
remains the only autologous chondrocyte technique
approved by the United States Food and Drug Administra-
tion (FDA) at present and is at least a 2-stage procedure. In a
review of 20 clinical studies of ACI, Iwasa et al43 reported
that femoral defect repairs had60% to 90% excellent-to-good
clinical results after 1 to 11 years. A second review of the
literature on ACI concluded that a void of strong, prospec-
tive randomized controlled data exists, with the majority of
success being documented in case series.20 A Cochrane
review performed to evaluate the efficacy and safety of ACI
identified 6 heterogeneous trials with 431 participants with
comparisons against mosaicplasty or microfracture tech-
niques. A conclusion was reached that insufficient evidence
was present to draw conclusions regarding the efficacy of
ACI, with methodological flaws of incomplete follow-up and
inadequate outcome reporting hindering the reported
results.85 One such study by Knutsen et al48,49 demon-
strated no significant difference in histological quality or
macroscopic result between ACI and microfracture at 2 or
5 years, although both patient groups experienced signifi-
cant clinical improvement. Furthermore, recent studies
have shown that the use of ACI as a revision option for a
failedmicrofracture procedure produces significantly worse
results compared with ACI used as a primary interven-
tion.65,72 Therefore, these recent studies suggest clinicians
should consider ACI as a primary method for the repair of
both large and small cartilage lesions without previous
marrow-stimulatory techniques (ie, microfracture) until
more high-level evidence studies refute these findings.
Inconsistency in the indications of use, whether for primary
repair or revision of failed microfracture, has undoubtedly
confounded the clinical result of ACI. Despite these obsta-
cles, recent newer studies have shown promising results. In
1 such study, second-look arthroscopy of ACI grafts without
augmentation carried out in 22 knees (32 lesions) demon-
strated normal/nearly normal grafts based on International
Cartilage Repair Society (ICRS) assessment, with hyaline/
hyaline-like tissue observed on 13 (65%) of 20 taken core
biopsy specimens.38 More importantly, satisfactory objec-
tive outcome scores were observed in 94.4% of patients at
24 months. In a more recent study by this group, ACI has
also been demonstrated to produce a hyaline-like repair,
with biomechanical properties comparable with native car-
tilage and superior to fibrocartilage repair via histology and
indentometry testing.39 As the largest reviews have demon-
strated, a level of uncertainty regarding theuse ofACI exists
in the literature at present, but newer, promising findings
reiterate that continued future study is warranted.85
Following the natural history of the use of ACI, the deve-
lopment of a bilayered collagen I/III membrane to provide a
blueprint for the replanted chondrocytes emerged in
response to complications associated with hypertrophy of
the periosteal flap. Collagen-covered ACI (CCACI), as this
was termed, has been used exclusively in Europe and
remains ‘‘off-label’’ for use in the United States. This tech-
nology advanced into a matrix-associated autologous
chondrocyte implantation (MACI)–type procedure, with
culturing of expanded chondrocytes into a matrix/
membrane before implantation. Despite these advances, a
recent study by Zeifang et al92 reported no difference in the
advanced MACI technique compared with the original peri-
osteal flap ACI technique in the repair of isolated full-
thickness defects of the femoral condyle.
Functional and radiographic findings have demon-
strated MACI to be an effective therapy for symptomatic,
large cartilage defects when compared with microfracture,
the current FDA-accepted ‘‘gold-standard.’’ The most
recent publication to directly compare microfracture with
MACI resulted from the SUMMIT (Demonstrate the Super-
iority of MACI implant to Microfracture Treatment) trial76
that showed significant improvement in the activities of
daily living and knee-related quality of life for patients
treated with MACI compared with microfracture. Repair
tissue quality was good as assessed by histology and mag-
netic resonance imaging (MRI), but no significant tissue
quality difference was shown between treatments. A low
number of treatment failures (nonresponders: MACI,
12.5% vs microfracture, 31.9%; P ¼ .016) was observed, and
there were no unexpected safety findings reported. MACI
offers a more efficacious alternative than microfracture
with a similar safety profile for the treatment of sympto-
matic articular cartilage defects of the knee, which is great
progress in the treatment of large, isolated chondral
lesions.76 However, at this time, no demonstrable effect
between MACI, CCACI, and ACI has been demonstrated
in clinical study.
A common drawback to all these procedures is the need
for a 2-stage surgical approach that requires harvest,
amplification of chondrocytes, and reoperation for implan-
tation. A variety of novel single-step techniques are now
emerging, including the use of a chondrocyte conductive/
inductive matrix with allogeneic fetal chondrocytes for
implantation in chondral defects, and have been described
as a means to generation of hyaline-like product. Known as
DeNovo ET, the technology would be available as an off-
the-shelf option that uses minced allograft donor cartilage
to fill chondral defects and has been demonstrated to gen-
erate cartilage similar to physiologic hyaline baseline.40,61
Other novel techniques are attempting to evolve a single-
step cartilage repair procedure,6,7,18 one such example
being the Cartilage Autograft Implantation System (CAIS).
In a preclinical animal study, Frisbie et al33 demonstrated
CAIS and ACI as superior to an empty defect (negative
control) in equine articular defects, with CAIS being super-
ior to ACI. In advancement to human clinical study, initial
results show strong functional outcomes that persist at 2-
year follow-up when compared withmicrofracture.14 In this
procedure, autologous hyaline cartilage was harvested
arthroscopically from a nonweightbearing region of the
notch or trochlear border and the harvested cartilage was
mechanically minced and affixed on a synthetic absorbable
scaffold using fibrin glue and implanted in an ACI-type
fashion. This was shown to be safe and feasible and
requires further study.14 In recent advances, multiple stud-
ies have documented several different techniques, some
combining microfracture with biocompatible matrices and
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others using novel cell mixtures alone, both of which have
shown the ability to proliferate a hyaline-like repair in
isolated defects.6,18 Certain techniques look to use stem
cells to augment the existing ACI protocol, achieving pro-
liferation and development in a single-step procedure.7
These types of innovation are significant, as a single-step
repair procedure would serve as a point-of-care surgical
procedure for the primary treatment of isolated, full-
thickness chondral lesions in the knee and decrease return
trips to the operating room. Further study will be needed to
assess repeatability of a hyaline-like cartilage product with
these surgical techniques. A review of the pros, cons, and
specific areas needed for future study in the use of cartilage
implants and biologic scaffolds is provided in Table 2.
STEM CELL THERAPY
Aside from a biologic delivery system of combined growth
factors (bone marrow aspirate/bone marrow concentrate
[BMA/BMC]), stem cells may also serve as an undeveloped
‘‘blueprint’’ capable of differentiating and re-creating a
structure as complex as the osteochondral unit and articu-
lar surface. Mesenchymal stem cells (MSCs) are resident
precursor cells that exist in large quantities across multiple
tissue types and retain the ability to regenerate and repair
tissue. The regenerative effects for the chondral surface are
a direct result of the ability of MSCs to aid in the structural
repair of the osteochondral unit while promoting anti-
inflammatory effects across the articular environment.28
In theory, the autologous collection and use of these cells
for repairing full-thickness chondral deficits may serve as a
‘‘magic bullet’’ with programmed growth factor releases and
alteration of the microenvironment milieu inherent to ana-
tomic cartilage development, regeneration, and repair.
MSCs reside in various tissues (bone marrow, adipose,
muscle, etc), are harvestable in large quantities,1,17,68 and
have been shown to produce a variety of extracellular
matrix proteins and molecules involved in the cellular pro-
cess of native tissue repair. In basic science settings, they
have also been shown to be reversible via specific induction
techniques to a pluripotent precursor. The identification of
several transcription factors, thought to play amajor role in
differentiation and the retention of pluripotent ability, has
allowed successful induction of pluripotency from
nonembryonic-derived cells. The generated ‘‘inducible-
pluripotent stem cells’’ are promising and currently under
study.74 Most important, in using these organized repair
blueprints, the joint microenvironment and dosing of pro-
anabolic anti-inflammatory signaling can be regulated by
intrinsic cellular feedback mechanisms rather than relying
on repeated iatrogenic dosing. The MSCs derived from adi-
pose, muscle, and synovium have been evaluated for their
ability to restore focal cartilage defects and reverse cata-
bolic joint environments of progressive OA via either
articular injection or scaffold implantation.
As stated above, promising results have demonstrated
reproducible hyaline-like cartilage product with proper cell
induction and stimulation across MSCs collected from var-
ious tissue types, including bone marrow, adipose tissue,
and synovium. The first MSCs identified and examined for
clinical use were bone marrow–derived MSCs (BMSCs),
primarily because of their high quantity in adult patients
and ease in collection.28,68 Clinical applications were
explored for both expandable cultured cells and concen-
trated unmodified aspirate (bone marrow aspirate concen-
trate [BMAC]). Used alone or in conjunction with other
biologic therapies (microfracture, collage scaffold, chondro-
cyte transfer, etc), BMAC collected from various bone mar-
row extraction sites have emerged as a therapy with good
chondrogenic and osteogenic potential.1,28,68 Fortier et al31
demonstrated improved full-thickness repair, confirmed
with histologic and MRI evidence, with the generation of
a filled chondral defect and increased integration with sur-
rounding cartilage when incorporated with microfracture.
Similar studies suggest that BMAC in combination with
collagen- or scaffold-covered defects promotes hyaline-like
cartilage development with a seamless incorporation of
new cartilage product.25,34 Preclinical animal studies with
BMSCs have also demonstrated generation of a stable,
hyaline-like cartilage product with the use of scaffold or
via intra-articular injection for delivery.62,93 In clinical
studies, symptoms of isolated defects and OA have shown
to be improved after surgical implantation of BMSCs with
a stable effect several years postoperatively. Repairs with
BMSCs have demonstrated both fibrocartilage and
hyaline-like tissue products,86,87 with some BMSC
implants achieving significant defect filling and congruity
TABLE 2
Pros, Cons, and Specific Areas Needed for Future Study
in the Use of Cartilage Implants and Biologic Scaffoldsa
Pros
 Able to bridge isolated, full-thickness cartilage defects
 Can restore function to previously damaged weightbearing
zone
 Single-step, point-of-care surgical techniques currently in
research
 Provides clinical option for large, full-thickness
osteochondral defects
Cons
 Inconsistent generation of hyaline-like versus fibrocartilage
product
 Resiliency of implant lacking compared with native articular
surface
 Currently accepted protocol requires 2 steps (2 operations)
 Lack of FDA-approved new implants or innovation
Needs for future study
 Environmental factors involved in generation of hyaline-like
product
 Innovation of currently accepted ACI protocol (ie, new
technology)
 Large-scale, prospective, multicenter trials needed for
outcome evidence
 Improved national and international collaboration in
research
 Collaboration with governing bodies to promote scientific
advancement
aACI, autologous chondrocyte implantation; FDA, Food and
Drug Administration (United States).
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with neighboring cartilage.37,46 Direct comparison
between ACI and BMSC implantation by Nejadnik
et al70 in 2010 showed a similar pattern of clinical and
subjective improvement up to 2 years postoperatively but
concluded BMSC as favorable because of a decrease in
operations (single-stage vs 2-stage), cost, and donor mor-
bidity compared with ACI.
Adipose tissue also serves as a reservoir for MSCs.
Adipose-derived MSCs (ADMSCs) can be recovered from
liposuction aspirates94 but can also be readily collected
from human infrapatellar fat pads22 and have the poten-
tial for differentiation into cartilage, as well as bone, ten-
don, and muscle.79 The incorporation of autologous
ADMSCs into scaffolds, after isolation and proper induc-
tion, with surgical implantation has shown to be success-
ful in repairing full-thickness chondral defects with
hyaline-like cartilage with seamless incorporation with
native cartilage. Further analysis of these repairs demon-
strated extracellular proteins, gene products, and surface
markers were found to be consistent with native hyaline
cartilage.21,60 Direct injection of ADMSCs, concentrated or
in combination with other biologic compounds, has demon-
strated improvement in clinical pain and function out-
comes without major adverse events.50,71 In an overall
review of the literature, consensus exists that ADMSCs
at baseline have lower chondrogenic potential compared
with either bone marrow– or synovial-derived cells.26,66,79
However, recent advances made in the augmentation of
ADMSCs with high-dose, combination growth factors
(including TGFb2 and BMPs) may increase this chondro-
genic potential, albeit with increased detrimental inflam-
matory reaction.28,47 This highlights the need for more
study of ADMSCs and growth factor stimulation prior to
application in clinical studies.
Synovial-derived stem cells are emerging as an addi-
tional promising source of MSCs, with greater chondro-
genic potential than ADMSCs or BMSCs and less
osteogenic potential.19,69 Animal studies have demon-
strated full-thickness lesion healing with an appearance
similar to neighboring cartilage and high histological cor-
relation scores. This suggests an increased chondrogenic
ability as well as great potential for reproducible hyaline-
like cartilage production, which would serve as an improve-
ment from existing cartilage regeneration techniques.
At present, there are no clinical comparisons available in
the literature regarding the optimal MSC source for carti-
lage regeneration. As mentioned above, correlations have
been drawn between increased chondrogenic capability and
the effectiveness of repair. However, as is seen with PRP and
BMAC, a complex interplay of inflammatorymodulation and
repair potential needs to be established for incorporation of a
consistent, hyaline-like product. Further characterization of
the physical and biochemical properties of presumed
‘‘repaired defects’’ is needed. An important study by Ando
et al2 demonstrated that despite excellent chondrogenesis
and defect filling, inferior tissue quality at the superior edge
of cartilage does not adequately retain water and establish a
resilient extracellular matrix. This will likely lead to an
eventual failure of the repair product due to the high level
of stress within an active joint. Therefore, continued study
regarding the chondrogenic potential of MSCs, the organi-
zation and development of the osteochondral unit, and the
interplay between environmental factors and intrinsic
cellular potential is needed to advance this aspect of regen-
erative medicine. A review of the pros, cons, and specific
areas needed for future study in the use of stem cells for
regeneration of articular cartilage is provided in Table 3.
IDENTIFIED BARRIERS TO RESEARCH
ADVANCEMENT AND CLINICAL
IMPLEMENTATION
The use of biologics, including PRP, growth factors, bioen-
gineered scaffolds, and stem cells, offers promising
improvements in the prevention and treatment of OA in
the active and aging populations. Isolated, full-thickness
cartilage lesions cause significant morbidity and loss of
function and initiate the inflammatory cascade toward dif-
fuse joint arthritis. Early diagnosis and cartilage restora-
tion/repair protocols, made available by continued
research and large clinical trials, may reverse the cascade
toward OA and provide additional years of pain control
and high function. The following is a summary of the
future direction for this field of study and what advances
or innovations need to be discovered through collabora-
tive, large-scale studies.
Earlier detection and diagnosis of isolated cartilage
injury must be achieved. The collagen network and proteo-
glycan content of cartilage becomes disrupted prior to mor-
phologic change of the articular surface and can therefore
TABLE 3
Pros, Cons, and Specific Areas Needed for Future Study
in the Use of Stem Cells for Regeneration
of Articular Cartilagea
Pros
 Numerous in vivo; can be derived from muscle, adipose, and
bone marrow
 Osteogenic and chondrogenic differentiation capacity
 Can regulate local immune environment
 Secretion of trophic factors to create a regenerative
microenvironment
Cons
 Risk for malignancy
 Repair tissue quality not equivalent to natural hyaline
cartilage
 Cannot be modified prior to reintroduction (eg, BMAC)
 Insufficient clinical evidence to overcome federal restrictions
Needs for future study
 Optimal delivery strategy (ie, injection, scaffold,
implantation, etc)
 Standard technique and dosing regimen
 Large-scale, prospective, multicenter trials needed for
outcome evidence
 Improved national and international collaboration in
research
 Collaboration with governing bodies to promote scientific
advancement
aBMAC, bone marrow aspirate concentrate.
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be paramount in the early diagnosis of isolated articular
deficits and diffuse osteoarthritic changes. However, often
a full-thickness cartilage deficit may be observed in the first
clinical encounter. Advanced compositional MRI tech-
niques that focus on early changes in the substructure of
the osteochondral unit (ie, ultrashort echo time [UTE]–T(2)*,
T2 mapping, and glycosaminoglycan chemical exchange-
dependent saturation transfer/delayed gadolinium-
enhanced MRI of cartilage [gagCEST/dGEMRIC]) may
provide an opportunity to prognosticate a full-thickness
deficit after a traumatic knee injury that normal MRI can-
not evaluate.5,10,41,42,88 This may influence weightbearing
protocols and activity level, but more importantly, may
provide clinicians an opportunity to treat the developing
lesion with a biological factor (ie, PRP, growth factor, or
MSC population) that encourages repair and prevents the
cascade toward a full-thickness deficit.36,75,84 For this clin-
ical scenario to be possible, standardization of these
advanced imaging techniquesmust first be achieved across
preclinical and clinical research studies. These noninva-
sive techniques must be further validated in their ability
to detect microstructure changes that can accurately prog-
nosticate further injury and also serve to better quantify
repair techniques as successful or unsuccessful in regener-
ating hyaline-like tissue that exhibits the mechanical and
biochemical properties of native cartilage. Furthermore,
research effortsmust also focus on establishing that a docu-
mented ‘‘hyaline-like regenerate on advanced imaging’’ has
equivalent functional testing and patient-reported out-
comes in clinical practice. In establishing this relationship,
significant changes to the clinical management and prog-
noses of articular defects can be made. Along with this goal
of early diagnosis, continued search for a blood- or tissue-
borne biomarker forOAwould be paramount in the preven-
tion or early treatment of OA. This would allow for the
development of screening standards for joint disease and
aid clinicians in their patient-specific diagnostic tests and
treatments based on the level of biomarker observed. More
studymust also be directed to the characteristics of an ideal
host for biologic therapy. The role of lifestyle, diet, baseline
activity level, and other medical comorbidities in biologic
treatments must be further elucidated. Further under-
standing of these factors and their role in regenerative
medicine will guide the use of autologous versus allogeneic
cellular products.
Once the diagnosis has been made and the host charac-
teristics analyzed, among the first questions that need to be
answered in developing the ideal biologic treatment are
what is/are the ideal cell type(s) for the repair of cartilage
lesions and what corresponding growth factors or intra-
articular environment will optimize the ability of these cells
to proliferate. A large number of studies have demonstrated
the anti-inflammatory and chondrogenic properties of var-
ious different cell types but no clear champion has emerged.
This is primarily due to a lack of standardization across
research protocols (ie, how cells are collected, how they are
cultured, what animal models are used, how results are
quantified, etc). There are currently more than 15 different
devices being used for the collection and production of an
autologous PRP product, with documented differences
noted across each preparation. This level of variability is
confounding and significantly detracts from the ability of
clinicians and researchers to establish a gold standard
regarding cell count, growth factor concentration, host
characteristics, and other variables. To achieve a level of
uniformity across techniques, more large-scale collabora-
tive efforts are needed. Large-scale data collection must
be invoked at both preclinical and clinical research levels
to generate valid conclusions regarding the ideal cell types,
biologic preparations, and growth factors needed to opti-
mize the regeneration of native, hyaline-like cartilage.
The remaining discussion must focus on the surgical
implant (ie, how will the chondrogenic and osteogenic cells
with appropriate factors be best integrated into the existing
cartilage lesion). In designing the optimal regenerative/
reparative scaffold, there are several factors that need to
be addressed. First, the implanted scaffold should be able to
re-create the entire osteochondral unit. The multiple levels
of this structure each contribute to the success of native
cartilage. Initial attempts at restoring native structure
have generated an inferior product that does not demon-
strate the resilience of healthy cartilage. This is likely due
to the paradigm of hydrostatic and sheer pressures across
the various substructures in the osteochondral unit and the
ability of the implanted scaffold/cellular product to repli-
cate this. A repair that does not balance the forces of the
stressful intra-articular unit, though initially hyaline-like
with uniform incorporation, will propagate and disrupt the
healed graft, leading to overall clinical failure. More studies
must be done in vitro and in vivo with advanced imaging
and quantitative compositional data so that scaffolds can be
characterized in an optimal fashion to replicate the func-
tion of the native osteochondral unit. When cartilage heal-
ing occurs in vivo, without biologic augmentation,
repopulation from the subchondral unit and the outer syno-
vial layer is observed.44 A scaffold should thus aim to repair
cartilage from the subchondral bone to the cartilage–synovial
fluid interface. The biologic and physical properties of re-
generating the entire osteochondral unit must be elucidated
in future works. Second, the implanted scaffold or graft
should be able to immediately load share so as to not alter
the forces applied across the healthy, native articular
surface. Advances in cell culture may achieve this level of
production, where hydrostatic and other mechanical forces
can be applied to the cellular grafts at early stages in their
development. This may allow for earlier weightbearing post-
operatively and a restoration of joint mechanics, and this
prolonged stimulationof thegraftmayactivatedevelopmental
cascades needed to optimize the entire osteochondral unit.
This level of advance will require a widely collaborative effort
across multiple levels of expertise to enhance the culture
strategies so that a ‘‘ready product’’ is introduced during
surgery on the isolated defect.
Last, scientific advancements in the laboratory and pre-
clinical setting have been delayed from advancement into
clinical practice due to regulations and restrictions from
the US FDA. This discussion regarding the biologic thera-
pies for rotator cuff, meniscus, and cartilage was well out-
lined in a recent review by Anz et al.3 In 1997, the US FDA
set forth in Title 21, Part 1271 of the Code of Federal
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Regulations, an approach to all articles ‘‘containing or con-
sisting of all human cells, tissues, and cellular and tissue-
based products (HCT/Ps) intended for implantation, trans-
plantation, infusion, or transfer into a human recipient’’
(US Department of Health and Human Service 21, CFR
Part 1271). A tiered approach based on assessment of
patient risk divides biologic products into a lower risk cate-
gory governed by section 361 of the Public Health Service
Act (PHSA) and a higher risk category regulated by section
351 of the PHSA. A ‘‘351 product’’ must follow tissue prac-
tices and manufacturing standards approved by the FDA
on a case-by-case basis and must also pass a premarket
approval process with clinical trials and an active investi-
gational new drug (IND) application in place. There are
notable time and financial costs required to adequately
achieve this proof of concept, and thus, the application of
products into clinical practice in a timely manner has been
prolonged. To differentiate a low-risk 361 product from a
high-risk 351 product, compounds must have been pre-
pared with minimal manipulation, intention for homolo-
gous use (must be reintroduced into a patient for its
native use), without combination of products, and with
safety data demonstrated by lack of systemic effects.3 If the
product vying for clinical use does not meet all 4 aforemen-
tioned criteria, it is labeled with 351 status and must garner
premarket approval as described above. Most orthopaedic
stem cell and growth factor interventions will require pas-
sage of 351 regulations. Specific examples of activities that
require 351 regulation by the FDA include culture expansion
of MSCs prior to reimplantation (more thanminimal manip-
ulation) and the use of ADSCs acquired from liposuction via
intra-articular injection (nonhomologous use).3,59 Without
completion of premarket approval and an approved biologics
license, stem cell products excluded from 361 status are
unable to be marketed or offered. Though warranted for the
continuation of safe therapies offered to patients, these reg-
ulations delay the advancement of newer, peer-reviewed
techniques from further clinical application.
With the acknowledgment of past progression of research
in the field of stem cells and biologic therapies, the FDA has
retained the right to regulate and monitor the use of stem
cells in clinical settings. An example of a regulatory
mechanism that limits clinical study and advancement is
the FDA regulation that cells must not leave the operating
room (ie, cannot bemodified or expanded in culture) prior to
their reimplantation.3 The impact of this regulation is
demonstrated when cultured and induced BMSCs are com-
pared with autologous BMAC. Culture expansion would
provide a fine-tuned approach to biologic augmentation;
however, because of these regulations, study into the spe-
cific characterization and augmentation of the BMSCs is
not clinically applicable at this time. Instead, a surgeon
must depend on recovery and reinjection without augmen-
tation to produce an adequate cell count and aspirate. How-
ever, unlike the characterized samples from laboratories,
yield from intraoperative recovery and reinjection is incon-
sistent and less well defined. Subsequently, this indirectly
confounds the patient-reported and objective outcomes
because the aspirates that are reinjected and evaluated for
clinical improvement have not been isolated, cultured, and
characterized, and therefore, conclusions about specific
active mediators can be difficult. This increases the varia-
bility of the treatment because a predetermined optimal
cell count or growth factor composition cannot be standar-
dized nor can a precise characterization of host stem cells,
or host PRP, be performed prior to reimplantation. Host
variability, the regional tissue source of the collected aspi-
rate(s), and potential inadequate collection all lead to
uncertainty regarding observed clinical outcomes. Despite
successful research advancements, specifically in ACI, there
has been minimal advancement of clinical trials and the
emergence of new technologies into the clinical setting.
Scientists and clinicians have to base their study design and
biologic augmentation off what is allowed under current reg-
ulation and not what has been shown in peer-reviewed stud-
ies to be effective and believed to be safe. Many have
approached this reality by adapting to the regulations rather
than attempting to advance a new technology through the
application process for a novel therapy. This is illustrated in
the fact that despite multiple studies demonstrating superior
results with new therapies in preclinical study compared
with previously accepted gold standard techniques,16,77,78,84
there have been no introductions of novel therapies since the
approval of ACI approximately 20 years ago.
The next several years should prove to be important in
setting the framework for the use of biologic strategies to
heal full-thickness cartilage defects and articular injury. At
present, experimental techniques, including the method of
production for a biologic compound or cellular concentrate,
patient population, and outcome measures, are variable,
making the production of a consensus statement or compar-
ing peer-reviewed works difficult. There is a need for a
collaborative effort, multicenter studies, and standardized
biologic regimens for the treatment of cartilage injury. Cell
populations and potential injectable compounds (ie, PRP,
BMAC, and MSCs) will need to be better defined as to their
composition of growth factors, profile of expression, and
their direct effect on the joint microenvironment. Combina-
tion therapies must be evaluated to better replicate the
anticatabolic, proanabolic, and organized manner of chon-
drocyte proliferation and incorporation. New experimental
techniques will need to be developed to allow for the devel-
opment of novel scaffolds capable of replicating the osteo-
chondral unit with preconditioned ability to bear stress
soon after implantation. This will also depend on
evidence-based characterization of the individual thera-
pies; otherwise, it may produce more confusion as to the
component parts of any combination therapy and how it
exerts its effect on damaged tissue. Last, partnering with
regulatory bodies will be important to allow for the colla-
borative efforts of scientists, engineers, and physicians to
advance clinical therapies capable of achieving a meaning-
ful increase in the functional status of patients.
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